Explore tools and strategies in quality improvement (QI) with this online activity series produced in collaboration with RealCME.
Over the course of several months, you will be able to participate in a QI initiative with a virtual healthcare system to improve the quality of care for patients eligible to receive immune checkpoint inhibitors. This initiative will include 3 CME-certified educational modules, released consecutively over several months, and collaborative telephone calls with our expert faculty to be held after the second and third modules are released.
1.5 AMA PRA Category 1 Credits™
Apr 26, 2018
Apr 26, 2019
- Immuno-oncology (IO) treatment options
- Quality improvement in IO
- Biomarkers in IO
- Immune-related adverse events
- Shared decision making
- Coming in August.
- Coming in November.
Joseph Jacobson, MDChief Quality Officer
Dana Farber Cancer Institute
Boston, Massachusetts, United States
Timothy Gilligan, MDCo-Director of the Excellence in Healthcare Communication
Cleveland, Ohio, United States
John B. A. G. Haanen, MD, PhDProfessor of Translational Immunotherapy of Cancer
University of Leiden
Netherlands Cancer Institute
Amsterdam, the Netherlands
The target audience for this initiative is physicians, physician assistants, nurse practitioners, registered nurses, and other healthcare providers who provide care for patients with cancer in North America and the European Union, including Switzerland and Israel.
- Develop optimum treatment strategies using checkpoint inhibitors to treat a variety of tumor types
- Create approaches to monitor and manage immune-related adverse events (irAEs) resulting from treatment with immune checkpoint inhibitors
- Discuss best practices related to shared decision making in clinical practice
- Describe foundational principles of quality improvement as they relate to healthcare
- Coming in August.
These activities are supported by educational grants from Bristol-Myers Squibb, EMD Serono, and Pfizer.
prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
prIME Oncology designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
These activities are provided by prIME Oncology.
Method of Participation
The posttest is available within the activity.
In order to receive credit, participants must successfully complete the online posttest with 75% or higher.
Disclosure of Relevant Financial Relationships
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Gilligan has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Haanen has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Jacobson has nothing to disclose in relation to this activity. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Ronald Viggiani, MD (medical director content reviewer/planner) – no relevant financial relationships
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.